Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02432586
Other study ID # STU 042014-061
Secondary ID
Status Completed
Phase N/A
First received March 10, 2015
Last updated June 21, 2017
Start date July 2014
Est. completion date January 2017

Study information

Verified date June 2017
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

18 preschool aged children and their families will attend structured, multidisciplinary, family-centered intensive education sessions over a 3-day weekend in a residential camp setting to address the unique challenges of managing type 1 diabetes mellitus in young children. A second 'booster' session, will be conducted 6 months later.


Description:

We propose to deliver a structured multidisciplinary family-centered intervention over a 3-day weekend, with a second similar "booster" session 6 months later. The intervention will be based at our regional diabetes camp, Camp Sweeney. The proposed camp encounters aim to provide:

- An opportunity for intensive education beyond that achievable in a single class, and without the unfavorable impacts of multiple weekday classes on family and work time.

- Varied educational modalities including didactic sessions, practical demonstrations and role playing.

- Close observation of each child throughout the day and night by experienced diabetes counselors and medical staff to identify and help correct maladaptive family behaviors.

- A safe environment where parents can participate in group therapy sessions without child care worries.

- An opportunity for age-appropriate child-centered educational and therapeutic activities.

- An opportunity for families to form mutually-supportive friendships.

- Fun weekends away where the parents have help caring for their diabetic children.

We will conduct this pilot study, which will enroll 18 preschool children age 3-5.5 years, with the goal of obtaining preliminary results for 15 subjects.

The primary outcome, to be determined approximately one month before and after each of the two camp sessions, is improvement in Hemoglobin A1c (HbA1c). This outcome will be compared with that of historical controls.

Exploratory Hypotheses:

Compared with pretreatment baseline and historical controls, subjects attending two 3-day sessions at a family diabetes camp will improve:

- HbA1c 3 months after the first camp session

- Hypoglycemia frequency, as measured by continuous glucose monitoring

- Medical system utilization, as measured by telephone call frequency and also by emergency room visits and hospitalizations

- Behavioral/QoL assessments, including the parents of young children version of the hypoglycemia fear survey (HFS-P-YC), the Behavioral Pediatrics Feeding Assessment Scale (BPFAS), and the general and diabetes modules of the PedsQL.

- Diabetes knowledge, assessed by questionnaire

- Development of friendships between subject families, assessed by questionnaire


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date January 2017
Est. primary completion date August 2016
Accepts healthy volunteers No
Gender All
Age group 34 Months to 68 Months
Eligibility Inclusion Criteria:

- Age 3-5.5 years old (+/- 2 months) at the date of first camp session they are eligible to join.

- Child and Parents fluent in either English or Spanish.

- Type 1 diabetes mellitus diagnosed for at least 10 months previous to date of first camp they are eligible to join.

- Taking insulin

- Custodial parent or guardian (preferable both parents or guardians) willing to attend both session of camp and the activities scheduled for them.

- Parent or guardian must sign consent before any study procedures are performed.

Exclusion Criteria:

- Neonatal diabetes (diagnosis in the first 3 months of life) or documented MODY; i.e., a likely genetic form of diabetes rather than an autoimmune etiology.

- Post-surgical diabetes (e.g., pancreatectomy for congenital hyperinsulinism). Such patients often cannot secrete glucagon, leading to a particularly severe inability to defend against hypoglycemia.

- Other severe chronic disease (e.g., cancer, cystic fibrosis) which in the judgment of the investigator is likely to significantly affect glycemic control.

- Patients cannot be taking systemic corticosteroids at enrollment because of adverse effects on glycemic control, but we will not disqualify subjects who require such therapy during the study. Inhaled or topical corticosteroids are permissible.

- Patients with hypothyroidism or hyperthyroidism must be clinically euthyroid and have free T4 and TSH within age-appropriate reference ranges at last medically indicated testing. Patients with out of range values may be retested after medication dose adjustment.

- Developmental delay or behavioral disorder in the patient of sufficient severity, in the judgment of the investigator, to interfere with group activities.

- Medical or psychiatric disorder in a parent of sufficient severity, in the judgment of the investigator, to interfere with group activities.

- Celiac disease is not an exclusion criterion.

Study Design


Intervention

Behavioral:
Intensive Education
Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Hemoglobin A1c one month pre-camp to one month post-camp Session 1 As compared to historical controls One month pre-camp, one month post-camp
Primary Change in Hemoglobin A1c one month pre-camp to one month post-camp Session 2 As compared to historical controls One month pre-camp, one month post-camp
Secondary Change in Hypoglycemia frequency one month pre-camp to one month post-camp Session 1 As measured by continuous glucose monitoring, and quantitated as area under the curve for blood glucoses <70 mg/dL. One month pre-camp, one month post-camp
Secondary Change in Hypoglycemia frequency one month pre-camp to one month post-camp Session 2 As measured by continuous glucose monitoring, and quantitated as area under the curve for blood glucoses <70 mg/dL. One month pre-camp, one month post-camp
Secondary Medical system utilization ( emergency room visits, hospitalizations related to T1DM) Composite measure. As compared to historical controls. Duration of participation in study, expected to be 10 months
Secondary Change in PedsQL Family Impact Module one month pre-camp to one month post-camp Session 1 Parent report One month pre-camp, one month post-camp
Secondary Change in PedsQL Family Impact Module one month pre-camp to one month post-camp Session 2 Parent report One month pre-camp, one month post-camp
Secondary Change in PedsQL Pediatric Quality of Life Inventory one month pre-camp to one month post-camp Session 1 Parent report for Toddlers, Parent report for Young Children, Young Child Report One month pre-camp, one month post-camp
Secondary Change in PedsQL Pediatric Quality of Life Inventory one month pre-camp to one month post-camp Session 2 Parent report for Toddlers, Parent report for Young Children, Young Child Report One month pre-camp, one month post-camp
Secondary Change in PedsQL Diabetes Module one month pre-camp to one month post-camp Session 1 Parent report for Toddlers, Parent report for Young Children, Young Child Report One month pre-camp, one month post-camp
Secondary Change in PedsQL Diabetes Module one month pre-camp to one month post-camp Session 2 Parent report for Toddlers, Parent report for Young Children, Young Child Report One month pre-camp, one month post-camp
Secondary Change in Hypoglycemia Fear Survey one month pre-camp to one month post-camp Session 1 Parents of young children version One month pre-camp, one month post-camp
Secondary Change in Hypoglycemia Fear Survey one month pre-camp to one month post-camp Session 2 Parents of young children version One month pre-camp, one month post-camp
Secondary Change in Behavioral Pediatrics Feeding Assessment one month pre-camp to one month post-camp Session 1 Behavior section One month pre-camp, one month post-camp
Secondary Change in Behavioral Pediatrics Feeding Assessment one month pre-camp to one month post-camp Session 2 Behavior section One month pre-camp, one month post-camp
See also
  Status Clinical Trial Phase
Completed NCT04476472 - Omnipod Horizon™ Automated Glucose Control System Preschool Cohort N/A
Completed NCT03635437 - Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes Phase 1/Phase 2
Completed NCT04909580 - Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes N/A
Active, not recruiting NCT00679042 - Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol Phase 3
Completed NCT03293082 - Preschool CGM Use and Glucose Variability in Type 1 Diabetes N/A
Completed NCT04016662 - Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Phase 4
Completed NCT02527265 - Afrezza Safety and Pharmacokinetics Study in Pediatric Patients Phase 2
Completed NCT03738865 - G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Phase 3
Completed NCT03240432 - Wireless Innovation for Seniors With Diabetes Mellitus N/A
Completed NCT03168867 - Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms) N/A
Completed NCT03674281 - The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System N/A
Completed NCT03669770 - Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
Recruiting NCT03682640 - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes Phase 2
Recruiting NCT04096794 - Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
Completed NCT02882737 - The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus N/A
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Withdrawn NCT02518022 - How to be Safe With Alcoholic Drinks in Diabetes N/A
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Completed NCT02558491 - Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM N/A
Completed NCT02562313 - A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog® Phase 1